- Trials with a EudraCT protocol (67)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
67 result(s) found for: CD25.
Displaying page 1 of 4.
EudraCT Number: 2008-001927-74 | Sponsor Protocol Number: SysVac01-C60P2 (PA/2008/2883) | Start Date*: 2009-01-16 |
Sponsor Name:University Hospitals Bristol NHS Foundation Trust | ||
Full Title: A PHASE II, OPEN LABEL, RANDOMISED, TWO CENTRE STUDY TO EVALUATE THE IMPORTANCE OF NATURALLY INDUCED IMMUNE REGULATION ON THE MUCOSAL IMMUNE RESPONSE TO MENINGOCOCCAL SEROGROUP B OUTER MEMBRANE VES... | ||
Medical condition: "Healthy volunteers" In this project we will establish whether naturally induced mucosal CD25+ T regulatory activity in adults and adolescents modulates the mucosal immune response to systemic Me... | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-002546-11 | Sponsor Protocol Number: HAN-HCC-002 | Start Date*: 2006-10-20 | |||||||||||
Sponsor Name:Medizinische Hochschule Hannover | |||||||||||||
Full Title: Offene Phase IIIb Studie zur Elimination von CD4+CD25+ regulatorischen T-Zellen bei Patienten mit fortgeschrittenem HCC durch die Gabe von Cyclophosphamid | |||||||||||||
Medical condition: Fortgeschrittenes Leberzellkarzinom | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006878-23 | Sponsor Protocol Number: APHP200023 | Start Date*: 2022-08-12 |
Sponsor Name:Assistance Publique Hopitaux Paris - APHP | ||
Full Title: Efficacy of Ruxolitinib as first line treatment in primary haemophagocytic lymphohistiocytosis (HLH) in children: a Phase 2, multicentre, non-comparative study R-HLH | ||
Medical condition: • Patient with Haemophagocytic lymphohistiocytosis (HLH) or lymphohistiocytic syndrome | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2008-006729-15 | Sponsor Protocol Number: IGG-GIFA-001 | Start Date*: 2008-11-25 | |||||||||||
Sponsor Name:ISTITUTO GIANNINA GASLINI | |||||||||||||
Full Title: OPEN PILOT STUDY, TWO ARMS, WITH HISTORIC CONTROL, MULTICENTRIC TO EVALUATE SAFETY AND EFFICACY OF ASSOCIATION WITH EVEROLIMUS AND LOW DOSES OF CYCLOSPORIN AND STEROIDS AFTER INDUCTION WITH MONOCLO... | |||||||||||||
Medical condition: pediatric patient after kidney transplant | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004303-19 | Sponsor Protocol Number: BSX - 001 | Start Date*: 2007-04-25 | |||||||||||
Sponsor Name:Cerimon Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of Basiliximab, with Concomitant Corticosteroids, in Steroid-Refractory Ulc... | |||||||||||||
Medical condition: Steroid-refractory ulcerative colitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) CZ (Prematurely Ended) SK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002231-27 | Sponsor Protocol Number: LOB-LEV-2005-02 | Start Date*: 2006-01-16 | |||||||||||
Sponsor Name:Clínica del Dr. Lobatón | |||||||||||||
Full Title: Estudio prospectivo, in vivo, aleatorizado, controlado, abierto, de fase IV, en grupos paralelos para medir el efecto de los antihistamínicos (levocetirizina 5 mg/día y ebastina 20 mg/día, vía oral... | |||||||||||||
Medical condition: Rinitis alérgica estacional | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024515-13 | Sponsor Protocol Number: VU-007 | Start Date*: 2011-03-22 | |||||||||||
Sponsor Name:VU University Medical Center | |||||||||||||
Full Title: Phase 1-2 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. | |||||||||||||
Medical condition: Metastatic renal cell cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-001474-25 | Sponsor Protocol Number: SVM9122 | Start Date*: 2012-01-02 |
Sponsor Name:Klinik für Dermatologie, Venerologie und Allergologie; Charité - Universitätsmedizin Berlin | ||
Full Title: A single-centre, single arm, open-label, exploratory trial of Interleukin-2 administered subcutaneously as neo-adjuvant treatment prior to sentinel lymph node biopsy(SLNB)/complete lymph node disse... | ||
Medical condition: The trial is planned in a neo-adjuvant setting for a 4-weeks period in Melanoma patients with stage III. The stage is to be discovered by ultrasound and veriefied by fine needle punctere and cytology. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2013-001599-40 | Sponsor Protocol Number: 23032013 | Start Date*: 2014-01-03 | ||||||||||||||||
Sponsor Name:Charité - Universitätsmedizin Berlin | ||||||||||||||||||
Full Title: Evaluation of the safety, tolerability, efficacy and immunological responses of the interleukin-2 analogue Aldesleukin (Proleukin®) in the treatment of systemic lupus erythematosus as prototypic au... | ||||||||||||||||||
Medical condition: Patients with systemic lupus erythematosus (SLE) and increased disease activity refractory to standard therapies. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002382-62 | Sponsor Protocol Number: RNS60-ALS | Start Date*: 2017-01-13 | |||||||||||||||||||||
Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI | |||||||||||||||||||||||
Full Title: The effects of RNS60 on ALS biomarkers | |||||||||||||||||||||||
Medical condition: Amyotrophic Lateral Sclerosis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2008-005109-20 | Sponsor Protocol Number: CRAD001ADE19 | Start Date*: 2009-06-09 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: 6-month, open-label, randomized, multicenter, prospective, controlled study to evaluate the efficacy, safety and tolerability of Everolimus in de novo renal transplant recipients participating in t... | |||||||||||||
Medical condition: renal transplantation | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006366-29 | Sponsor Protocol Number: IRST172.01 | Start Date*: 2009-04-07 | |||||||||||
Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI | |||||||||||||
Full Title: IMMUNOTHERAPY OF MAINTENANCE IN THE PATIENTS WITH METASTATIC MELANOMA, CLINICAL BENEFIT AFTER CHEMOTHERAPY | |||||||||||||
Medical condition: There is a preclinical and clinical rational that supports a synergic effect of the combination of IL-2, RA and PEG-IFN. Maintenance therapy prolongs time to progression. It is also to note the lo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-023122-21 | Sponsor Protocol Number: PB002 | Start Date*: 2011-11-08 | ||||||||||||||||
Sponsor Name:King's College London [...] | ||||||||||||||||||
Full Title: Pro-Bono 2- A prospective study of loss of bone mineral density in patients with HIV over time: implications for clinical practice and therapeutic options: Vitamin D sub study. | ||||||||||||||||||
Medical condition: HIV | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-002795-13 | Sponsor Protocol Number: TACRO-Omics | Start Date*: 2020-04-23 |
Sponsor Name:Fundación de Investigación Hospital Universitario La Paz | ||
Full Title: Identification of "omic" biomarkers and their inter and intra-individual variability that allow improvement in the individualization of tacrolimus: uncontrolled clinical trial in pediatric patients... | ||
Medical condition: Pediatric patients with renal transplantation (under stable treatment with tacrolimus as immunosuppressant) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004799-50 | Sponsor Protocol Number: PNEUMOREG | Start Date*: 2015-02-13 |
Sponsor Name:Federico Martinon Torres | ||
Full Title: Evaluation of the immunoregulatory role of pneumococcal conjugate vaccination in pediatric patients with allergic asthma or type 1 diabetes mellitus versus pediatric population control. | ||
Medical condition: Allergic asthma and type 1 diabetes mellitus in pediatric subjects. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-003631-36 | Sponsor Protocol Number: RG_12-124 | Start Date*: 2015-02-10 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: CALiBRe: Assessment of the Mechanism of Action of idelalisib (CAL-101) in B-cell Receptor Pathway Inhibition in CLL | |||||||||||||
Medical condition: Chronic lymphocytic leukaemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018491-24 | Sponsor Protocol Number: 31295 | Start Date*: 2010-07-15 | |||||||||||
Sponsor Name:Vrije Universiteit Medical Center | |||||||||||||
Full Title: Effect of aminobisphosphonates and statins on circulating Vy9Vd2-T cells | |||||||||||||
Medical condition: patients with malignant bone metastases | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-001409-10 | Sponsor Protocol Number: FATIMS1.0 | Start Date*: 2013-08-08 | |||||||||||
Sponsor Name:Odense University Hospital | |||||||||||||
Full Title: FATIMS - Fampyra and T cell Immunity in Multiple Sclerosis; a study of the Fampyra induced immunomodulatory T cell responses in MS | |||||||||||||
Medical condition: Multiple Sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-001567-55 | Sponsor Protocol Number: DAC-1012 | Start Date*: 2006-06-23 |
Sponsor Name:Protein Design Labs, Inc. | ||
Full Title: A Phase II, Randomized, Double-Blinded, Placebo-Controlled, Multi-Center Study of Subcutaneous Daclizumab in Patients with Active, Relapsing Forms of Multiple Sclerosis | ||
Medical condition: This study is performed in patients with relapsing forms of Multiple Sclerosis. Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS), thought ... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) GB (Completed) ES (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001288-26 | Sponsor Protocol Number: DASAHIVCURE | Start Date*: 2022-08-18 | |||||||||||
Sponsor Name:IDIBAPS | |||||||||||||
Full Title: Safety, tolerance and antiretroviral activity of dasatinib: a pilot clinical trial in patients with recent HIV-1 infection | |||||||||||||
Medical condition: Recent HIV-1 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
